Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, TD Cowen Analyst Says

Key Points

• TD Cowen raised Halozyme Therapeutics’ price target to $130 from $105 and maintained a “buy” rating, implying approximately 18.7% upside from the reported $109.50 share price.
• Analyst sentiment is broadly positive: nine analysts rate the stock “buy,” while the consensus rating is “Moderate Buy” with an average price target of $96.50.
• Halozyme reported stronger-than-expected quarterly results, including $2.28 adjusted EPS versus the $1.79 estimate and $481 million in revenue, up 47.7% year over year; the company also issued fiscal 2026 EPS guidance of $8.65–$9.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) had its target price increased by stock analysts at TD Cowen from $105.00 to $130.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. TD Cowen's price target would suggest a potential upside of 18.72% from the company's current price.

HALO has been the subject of a number of other reports. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the company a "neutral" rating in a research report on Thursday, October 8th. Leerink Partners raised Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $83.00 to $110.00 in a report on Friday, August 7th. Citizens Jmp raised their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a research note on Friday, August 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $96.50.

Halozyme Therapeutics Price Performance

HALO traded down $1.58 on Tuesday, hitting $109.50. 830,748 shares of the company's stock were exchanged, compared to its average volume of 1,926,646. The stock has a market cap of $12.43 billion, a price-to-earnings ratio of 32.65, a P/E/G ratio of 0.42 and a beta of 0.88. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $116.85. The firm has a 50-day moving average price of $106.78 and a 200-day moving average price of $83.54. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. During the same quarter in the prior year, the company earned $1.54 EPS. Halozyme Therapeutics's revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts anticipate that Halozyme Therapeutics will post 8.25 earnings per share for the current year.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,482,605.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the sale, the director directly owned 58,839 shares of the company's stock, valued at approximately $6,339,313.86. This trade represents a 24.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock valued at $13,538,046 in the last three months. Corporate insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Horizon Investment Services LLC bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $2,254,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Halozyme Therapeutics during the 2nd quarter worth $1,025,000. Chase Investment Counsel Corp bought a new position in Halozyme Therapeutics during the 2nd quarter worth $2,035,000. Great Lakes Advisors LLC bought a new position in shares of Halozyme Therapeutics during the second quarter worth about $2,821,000. Finally, WINTON GROUP Ltd grew its position in shares of Halozyme Therapeutics by 704.6% during the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company's stock worth $4,723,000 after acquiring an additional 52,848 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.